Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
DTC | CBOE Canada | CAD | Real-time | |
DTC | CSE | CAD | Delayed |
Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Name | Age | Since | Title |
---|---|---|---|
Sebastien Plouffe | 51 | 2020 | CEO, President & Director |
Raimar Lobenberg | 57 | 2021 | Independent Director |
Sarkis Meterissian | 61 | 2021 | Independent Director |
Patrick Joseph Meagher | 37 | 2020 | CFO & Director |
Moutih Rafei | 41 | 2020 | Chief Scientific Officer & Director |
Kwin Grauer | - | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review